Building a sickle cell disease screening program in the Republic of Uganda: the Uganda Sickle Surveillance Study (US3) with 3 years of follow-up screening results. by Kiyaga, Charles et al.
Kiyaga, Charles; Hernandez, Arielle G; Ssewanyana, Isaac; McElhin-
ney, Kathryn E; Ndeezi, Grace; Howard, Thad A; Ndugwa, Christo-
pher M; Ware, Russell E; Aceng, Jane R (2018) Building a sickle cell
disease screening program in the Republic of Uganda: the Uganda
Sickle Surveillance Study (US3) with 3 years of follow-up screening
results. BLOOD ADVANCES, 2 (Suppl). pp. 4-7. ISSN 2473-9529
DOI: https://doi.org/10.1182/bloodadvances.2018GS110951
Downloaded from: http://researchonline.lshtm.ac.uk/4652089/
DOI: 10.1182/bloodadvances.2018GS110951
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
GLOBAL CAPACITY-BUILDING SHOWCASE
Building a sickle cell disease screening program in the Republic of Uganda:
the Uganda Sickle Surveillance Study (US3) with 3 years of follow-up
screening results
Charles Kiyaga,1 Arielle G. Hernandez,2,3 Isaac Ssewanyana,1 Kathryn E. McElhinney,2 Grace Ndeezi,4 Thad A. Howard,2
Christopher M. Ndugwa,4 Russell E. Ware,2,3,5 and Jane R. Aceng6
1Central Public Health Laboratories, Ministry of Health, Kampala, Uganda; 2Division of Hematology and 3Global Health Center, Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH; 4Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda; 5Department of Pediatrics, University of
Cincinnati College of Medicine, Cincinnati, OH; and 6Ministry of Health, Kampala, Uganda
Background
The prevalence of sickle cell disease (SCD) in the Republic of Uganda is higher than in the United
States, but there are no accurate countrywide data and no newborn screening program has been
established. The Early Infant Diagnosis (EID) program is well established to analyze dried blood spots
(DBSs) collected from HIV-exposed infants (ie, those born to HIV-positive mothers). HIV-positive infants
are identified and placed into specialty care.
At the request of the Uganda Ministry of Health, a partnership was developed between Cincinnati
Children’s Hospital Medical Center, Makerere University, and the Uganda Central Public Health
Laboratories (CHPL) to build local laboratory capacity for testing DBSs for sickle cell trait (SCT) and
SCD.
The Uganda Sickle Surveillance Study (US3) was designed to identify SCT or SCD in DBSs collected
throughout the national EID program. After US3, screening commenced in high-burden districts with
local capacity built to provide clinical care for affected infants.
Objectives
To build local capacity for laboratory skills with the following specific objectives:
c Establish a national sickle cell laboratory with appropriate equipment and reagents,
c Train local technologists to test all DBSs received by the EID program, and
c Analyze the data to determine the countrywide burden and create a geospatial map of SCT and
SCD.
To build local capacity to improve clinical management of SCD with the following specific objectives:
c Perform educational training workshops in high-burden districts,
c Teach local health care providers about the rationale and benefits of testing at-risk children for SCD,
and
c Initiate public awareness through health fairs and radio announcements to boost screening efforts.
Forming the partnership
Uganda Ministry of Health
c Commissioned up-to-date data across the country regarding the sickle cell burden,
c Prioritized high-burden districts to provide limited resources for sickle cell interventions and
improvements through primary care, and
c Offered to leverage health policy agendas and mobilize funding for sustainable sickle cell services.
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Uganda CPHL identified local laboratory
technologists for training
c Procured all reagents with in-country vendors and
c Launched the US3 study and the follow-on sickle cell testing
campaign.
Cincinnati Children’s Hospital Medical Center
c Purchased all required laboratory equipment and reagents to
launch the US3 project;
c Provided technical expertise in sickle cell testing methodologies
and training, including weekly Skype calls with quality assess-
ments; and
c Conducted remote monitoring and analysis of results to curate
data in real time.
Makerere University College of Health Sciences
c Provided an academic home for the sickle screening efforts
including local institutional review board approvals,
c Facilitated announcement and discussion of the main results at
the end of the US3 study, and
c Performed educational training in high-burden districts to in-
crease screening and to establish local sickle cell clinics at the
district hospitals.
Initial US3 screening results
US3
c In all, 97 631 samples were tested from 2014 to 2015 (Table 1).
c The overall prevalence of SCT was 13.3% and the prevalence
of SCD was distribution was noted across Uganda with the
highest burden in central regions.
Screening and training efforts
c Initiation in selected districts with the highest prevalence of
SCT and SCD.
c Wave 1 (October 2014) included Gulu and Lira districts with
high populations.
c Wave 2 (April-May 2015) included Dokolo, Jinja, Kampala, Kitgum,
Oyam, and Tororo.
c Wave 3 (July-August 2016) included Alebtong, Agago, Amo-
latar, Apac, Bundibugyo, Lamwo, Luwero, Mityana, Mubende, and
Pader.
Table 1. Sickle cell screening in US3 and the post-US3 period
Region of Uganda
US3 (1 year)
(97 631 samples)
Post-US3 (3 years)
(112 352 samples)
SCT (%) SCD (%) SCT (%) SCD (%)
Central 1 1896 (12.9) 69 (0.5) 2497 (13.1) 144 (0.8)
Central 2 1566 (14.1) 94 (0.8) 1646 (14.4) 128 (1.1)
East Central 1306 (19.9) 96 (1.5) 2128 (19.2) 225 (2.0)
Kampala 1835 (13.6) 90 (0.7) 3533 (13.7) 235 (0.9)
Mid-Eastern 752 (15.5) 60 (1.2) 1004 (17.4) 115 (2.0)
Mid-Northern 2445 (19.2) 160 (1.3) 4067 (18.5) 394 (1.8)
Mid-Western 1431 (11.1) 64 (0.5) 848 (14.5) 59 (1.0)
North-Eastern 702 (15.8) 46 (1.0) 1100 (16.4) 100 (1.5)
South-Western 631 (4.6) 23 (0.2) 135 (6.4) 3 (0.1)
West Nile 415 (13.8) 14 (0.5) 422 (16.5) 19 (0.7)
Total 12 979 (13.3) 716 (0.7) 17 380 (15.5) 1422 (1.3)
Samples were collected using targeted screening from the districts with the highest
burden. Results confirm the high burden of SCT and SCD in Uganda, especially in the East
Central and Mid-Northern regions.
Figure 2.
Figure 3.Figure 1.
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Education and community outreach
c Sickle cell education and training about diagnostic testing and
the new CPHL screening program was made available for health
care providers.
c Affected infants and children were referred to local district
hospitals for specialized care, using teaching guidelines pro-
vided by national health care experts.
c Program fundraising efforts included an annual Buganda Kingdom
Fun Run and Outreach screening events.
c World Sickle Cell Day celebration was held on June 19.
Post-US3 screening results
Targeted screening of high-burden districts
c 112 352 samples were tested from 2015 to 2018 (Table 1).
c The prevalence of SCT (15.5%) and SCD (1.3%) was higher
than in the original US3 study.
Uganda National Sickle Cell Laboratory
c After the local laboratory reached its maximum capacity,
the new CPHL was expanded to include a large sickle cell
laboratory.
c This laboratory offers free sickle cell testing to babies, toddlers,
and adults.
Upcoming research objectives
c Obtain follow-up data on babies identified with SCD;
c Explore the observed comorbidity between SCD and HIV;
c Characterize hemoglobin variants identified during sickle cell
surveillance efforts;
c Characterize genetic modifiers of SCD such as alpha-
thalassemia trait or G6PD deficiency, using DNA-based technol-
ogy; and
c Investigate isolated districts with high or low prevalence of SCT
to determine the influence of environmental, social, and genetic
factors.
Figure 4.
Figure 5. Prevalence of sickle cell trait in 112 districts in Uganda. Reproduced from
Ndeezi G et al, Lancet Glob Health. 2016;4(3):e195-e200, with permission.
Figure 6.
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